M
Michael Clearfield
Researcher at Touro University California
Publications - 86
Citations - 16178
Michael Clearfield is an academic researcher from Touro University California. The author has contributed to research in topics: Myocardial infarction & National Cholesterol Education Program. The author has an hindex of 30, co-authored 85 publications receiving 15013 citations. Previous affiliations of Michael Clearfield include Harvard University & University of North Texas Health Science Center.
Papers
More filters
Journal ArticleDOI
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
John R. Downs,Michael Clearfield,Stephen E. Weis,Edwin J. Whitney,Deborah R. Shapiro,Polly A. Beere,Alexandra Langendorfer,Evan A. Stein,William Kruyer,Antonio M. Gotto +9 more
TL;DR: Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL- C levels and supports the inclusion of HDL-C in risk-factor assessment and the need for reassessment of the National Cholesterol Program guidelines.
Journal ArticleDOI
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Naveed Sattar,David Preiss,Heather Murray,Paul Welsh,Brendan M. Buckley,Anton J. M. de Craen,Sreenivasa Rao Kondapally Seshasai,John J.V. McMurray,Dilys J. Freeman,J. Wouter Jukema,Peter W. Macfarlane,Chris J. Packard,David J. Stott,Rudi G. J. Westendorp,James Shepherd,Barry R. Davis,Sara L. Pressel,Roberto Marchioli,Rosa Maria Marfisi,Aldo P. Maggioni,Luigi Tavazzi,Gianni Tognoni,John Kjekshus,Terje R. Pedersen,Thomas J. Cook,Antonio M. Gotto,Michael Clearfield,John R. Downs,Haruo Nakamura,Yasuo Ohashi,Kyoichi Mizuno,Kausik K. Ray,Ian Ford +32 more
TL;DR: A meta-analysis of published and unpublished data found that statin therapy is associated with a slightly increased risk of development of diabetes, but the risk is low both in absolute terms and when compared with the reduction in coronary events.
Journal ArticleDOI
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
Paul M. Ridker,Nader Rifai,Michael Clearfield,John R. Downs,Stephen E. Weis,J. Shawn Miles,Antonio M. Gotto +6 more
TL;DR: As expected, lovastatin was effective in preventing coronary events in participants whose base-line ratio of total cholesterol to high-de...
Journal ArticleDOI
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events☆
TL;DR: Statin therapy may be effective in the primary prevention of coronary events among subjects with relatively low lipid levels but with elevated levels of C-reactive protein.
Journal ArticleDOI
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Paul M. Ridker,Brendan M. Everett,Aruna D. Pradhan,Jean G. MacFadyen,Daniel H. Solomon,Elaine Zaharris,Virak Mam,Ahmed A. K. Hasan,Yves Rosenberg,Erin Iturriaga,Milan Gupta,Michelle Tsigoulis,Subodh Verma,Michael Clearfield,Peter Libby,Samuel Z. Goldhaber,Roger Seagle,Cyril Ofori,Mohammad Saklayen,Samuel Butman,Narendra Singh,Michel R. Le May,Olivier F. Bertrand,James C. Johnston,Nina P. Paynter,Robert J. Glynn,Cirt Investigators +26 more
TL;DR: Among patients with stable atherosclerosis, low‐dose methotrexate did not reduce levels of interleukin‐1β, interleUKin‐6, or C‐reactive protein and did not result in fewer cardiovascular events than placebo and was associated with elevations in liver‐enzyme levels, reductions in leukocyte counts and hematocrit levels, and a higher incidence of non–basal‐cell skin cancers than placebo.